Daxor CEO Michael Feldschuh purchases over $16,000 in stock

Published 07/04/2025, 20:26
Daxor CEO Michael Feldschuh purchases over $16,000 in stock

Michael Feldschuh, the Chief Executive Officer of Daxor Corp (AMEX:NASDAQ:DXR), recently acquired 2,063 shares of the company's common stock. The transaction, which took place on April 4, 2025, amounted to a total value of approximately $16,277, with shares priced at $7.89 each. Following this purchase, Feldschuh's direct ownership in Daxor stands at 212,694 shares. This move reflects continued confidence in the company from its executive leadership, coming at a time when the stock trades near $7.75, significantly below analyst targets ranging from $22 to $25.According to InvestingPro data, Daxor has maintained profitability over the last twelve months, though it faces some near-term challenges with liquidity. The stock's negative beta of -0.06 suggests it often moves independently of broader market trends. For deeper insights into Daxor's financial health and growth prospects, including additional ProTips and comprehensive analysis, investors can access the full Pro Research Report on InvestingPro.

In other recent news, Daxor Corporation reported a remarkable 116.5% increase in revenue for Q4 2024, marking a significant milestone as the company achieved cash flow breakeven in Q1 2025. This financial performance underscores the company's robust growth trajectory, supported by innovative product developments and strategic market expansion. Daxor is also in the process of resubmitting its next-generation blood volume analyzer for FDA approval, which could further enhance its market presence. At a cardiology event, the company's Blood Volume Analyzer (BVA-100®) garnered significant attention, with research presented by Dr. Marat Fudim from Duke University Health highlighting its advantages over traditional pressure-based assessments for heart failure patients. The technology's ability to provide precise blood volume measurements has been emphasized as crucial for optimizing patient treatment and outcomes. Additionally, Daxor continues to expand its partnerships with academic institutions and community hospitals, broadening the use of its technology across multiple medical disciplines. The company's strategic initiatives include acquiring new diagnostic radiopharmaceuticals and transitioning to a 1934 Act company designation, aiming to enhance its market positioning. These developments reflect Daxor's ongoing commitment to advancing healthcare through innovative solutions in fluid management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.